In: Obesity

Maridebart cafraglutide

Amgen · AMG 133

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
19 active
32 in total · 7 in the EU
Targets
 

What this is

How it works
Copies GLP-1, a gut hormone that lowers appetite and blood sugar, and blocks the receptor for GIP, another gut hormone.GLP-1 agonist + GIPR antagonist antibody
How it’s given
“Participants will receive maridebart cafraglutide as SC injections.”In the company’s words, NCT07225686 on ClinicalTrials.gov
Tested for
Obesity (11 trials), Overweight (8 trials), Obstructive Sleep Apnea (2 trials), Diabetes Mellitus, Type 2 (2 trials), Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Obesity Disease, Obesity or Overweight, Heart Failure With Preserved Ejection Fraction and 5 more
Main trialPhase 3
“The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.”In the company’s words, NCT06858878 on ClinicalTrials.gov
Other names
MariTide · AMG 133

Other drugs for Obesity

All 157 drugs for Obesity

Coming up12

Changes1

Last 90 days

Trials32

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 21 Jan 2027 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Phase 3Active, not recruiting 21 Jan 2027 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Phase 3Active, not recruiting 27 Apr 2027 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Phase 3Recruiting 16 Jun 2027 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Phase 3Active, not recruiting 20 Aug 2027 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Phase 3Active, not recruiting 30 Aug 2027 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
Phase 3Recruiting 26 Dec 2027 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Phase 3Recruiting 26 Dec 2027 Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Phase 3Recruiting 3 Jan 2028 Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Phase 3Recruiting 30 Jun 2028 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Phase 3Active, not recruiting 30 Jun 2028 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Phase 3Recruiting 6 Sep 2028 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Phase 2Active, not recruiting 6 Oct 2025 A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Phase 2Active, not recruiting 25 Aug 2027 A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Phase 1Active, not recruiting 15 Nov 2026 A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Phase 1Active, not recruiting 18 Nov 2026 Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Phase 1Not yet recruiting 23 Mar 2027 Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Phase 1Not yet recruiting 26 Jul 2027 Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Phase 1Recruiting 20 Dec 2027 Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Phase 2Completed 8 Oct 2024 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Phase 1Completed 8 Apr 2022 Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
Phase 1Completed 18 Nov 2022 Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Phase 1Completed 27 Aug 2024 A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
Phase 1Completed 27 Dec 2024 A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
Phase 1Completed 9 May 2025 A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
Phase 1Completed 22 May 2025 A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
Phase 1Completed 21 Nov 2025 A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
Phase 1Completed 26 Nov 2025 The Effect of AMG 133 on Gastric Emptying
Phase 1Completed 26 Feb 2026 A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function
Phase 1Completed 28 May 2026 Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
Phase 1Completed 2 Jul 2026 A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Phase 1Completed 27 Aug 2026 Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Maridebart cafraglutide

Following is part of Solo: you see every change to Maridebart cafraglutide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in